Literature DB >> 8101486

A newly recognized point mutation in the cytochrome b558 heavy chain gene replacing alanine57 by glutamic acid, in a patient with cytochrome b positive X-linked chronic granulomatous disease.

T Ariga1, Y Sakiyama, K Tomizawa, S Imajoh-Ohmi, S Kanegasaki, S Matsumoto.   

Abstract

Molecular genetic analysis was performed in a patient with cytochrome b positive X-linked chronic granulomatous disease. A previous Southern blot study, using a cytochrome b heavy chain cDNA as probe, revealed a Pst I restriction fragment pattern for the cytochrome b heavy chain gene (CYBB) different to that of normal individuals. Since restriction length polymorphism with Pst I has never been observed in control individuals and no abnormal restriction fragment patterns in the patient's CYBB was detected with seven other enzymes used, we focussed on the single Pst I site in the CYBB cDNA as being the only mutation site responsible for his disease. A fragment of the patient's cDNA which included the Pst I site was amplified by reverse polymerase chain reaction, and loss of the Pst I site in the fragment was confirmed by incubation with Pst I. Subsequent sequence analysis of the fragment revealed a point mutation in the Pst I site (cytosine to adenine), substituting glutamic acid for alanine at position 57.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101486     DOI: 10.1007/bf01955051

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Chronic granulomatous disease presenting in a 69-year-old man.

Authors:  B L Schapiro; P E Newburger; M S Klempner; M C Dinauer
Journal:  N Engl J Med       Date:  1991-12-19       Impact factor: 91.245

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  DNA polymorphism of the C4 genes. A new marker for analysis of the major histocompatibility complex.

Authors:  A S Whitehead; D E Woods; E Fleischnick; J E Chin; E J Yunis; A J Katz; P S Gerald; C A Alper; H R Colten
Journal:  N Engl J Med       Date:  1984-01-12       Impact factor: 91.245

4.  Point mutations in the beta-subunit of cytochrome b558 leading to X-linked chronic granulomatous disease.

Authors:  B G Bolscher; M de Boer; A de Klein; R S Weening; D Roos
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

5.  Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558.

Authors:  D Rotrosen; M E Kleinberg; H Nunoi; T Leto; J I Gallin; H L Malech
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

6.  Genetic heterogeneity in patients with X-linked recessive chronic granulomatous disease.

Authors:  T Ariga; M Nakanishi; K Tomizawa; S Imajoh-Ohmi; S Kanegasaki; Y Sakiyama; S Matsumoto
Journal:  Pediatr Res       Date:  1992-05       Impact factor: 3.756

7.  CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter.

Authors:  D G Skalnik; E C Strauss; S H Orkin
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

8.  Topology of cytochrome b558 in neutrophil membrane analyzed by anti-peptide antibodies and proteolysis.

Authors:  S Imajoh-Ohmi; K Tokita; H Ochiai; M Nakamura; S Kanegasaki
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Impaired granulocyte superoxide production and prolongation of the respiratory burst due to a low-affinity NADPH-dependent oxidase.

Authors:  S B Shurin; H J Cohen; J C Whitin; P E Newburger
Journal:  Blood       Date:  1983-09       Impact factor: 22.113

View more
  6 in total

Review 1.  Hematologically important mutations: X-linked chronic granulomatous disease (third update).

Authors:  Dirk Roos; Douglas B Kuhns; Anne Maddalena; Joachim Roesler; Juan Alvaro Lopez; Tadashi Ariga; Tadej Avcin; Martin de Boer; Jacinta Bustamante; Antonio Condino-Neto; Gigliola Di Matteo; Jianxin He; Harry R Hill; Steven M Holland; Caroline Kannengiesser; M Yavuz Köker; Irina Kondratenko; Karin van Leeuwen; Harry L Malech; László Marodi; Hiroyuki Nunoi; Marie-José Stasia; Anna Maria Ventura; Carl T Witwer; Baruch Wolach; John I Gallin
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

2.  Two novel point mutations in the cytochrome b 558 heavy chain gene, detected in two Japanese patients with X-linked chronic granulomatous disease.

Authors:  T Ariga; Y Sakiyama; S Matsumoto
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

3.  A 15-base pair (bp) palindromic insertion associated with a 3-bp deletion in exon 10 of the gp91-phox gene, detected in two patients with X-linked chronic granulomatous disease.

Authors:  T Ariga; Y Sakiyama; S Matsumoto
Journal:  Hum Genet       Date:  1995-07       Impact factor: 4.132

4.  Detection of gp91-phox precursor protein in B-cell lines from patients with X-linked chronic granulomatous disease as an indicator for mutations impairing cytochrome b558 biosynthesis.

Authors:  C D Porter; F Kuribayashi; M H Parkar; D Roos; C Kinnon
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

5.  Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia.

Authors:  Tohru Fujiwara; Minami Yamada; Koichi Miyamura; Yasuo Tomiya; Kenichi Ishizawa; Hideo Harigae; Junichi Kameoka; Masayoshi Minegishi; Shigeru Tsuchiya; Takeshi Sasaki
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

Review 6.  Genetics and immunopathology of chronic granulomatous disease.

Authors:  Marie José Stasia; Xing Jun Li
Journal:  Semin Immunopathol       Date:  2008-05-29       Impact factor: 11.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.